SwePub
Sök i LIBRIS databas

  Extended search

L773:2050 6406
 

Search: L773:2050 6406 > Single-centre exper...

Single-centre experience with anti-tumour necrosis factor treatment in budesonide-refractory microscopic colitis patients

Daferera, Niki (author)
Linköpings universitet,Avdelningen för neuro- och inflammationsvetenskap,Medicinska fakulteten
Hjortswang, Henrik (author)
Linköpings universitet,Medicinska fakulteten,Avdelningen för neuro- och inflammationsvetenskap,Region Östergötland, Magtarmmedicinska kliniken
Ignatova, Simone (author)
Linköpings universitet,Avdelning för neurobiologi,Medicinska fakulteten,Region Östergötland, Klinisk patologi
show more...
Münch, Andreas, 1970- (author)
Linköpings universitet,Medicinska fakulteten,Avdelningen för neuro- och inflammationsvetenskap,Region Östergötland, Magtarmmedicinska kliniken
show less...
 (creator_code:org_t)
2019-11
2019
English.
In: United European Gastroenterology journal. - : SAGE PUBLICATIONS INC. - 2050-6406 .- 2050-6414. ; 7:9, s. 1234-1240
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Background: Microscopic colitis is an inflammatory bowel disease that causes chronic, watery diarrhoea. Microscopic colitis is usually effectively treated with budesonide, but some patients are refractory. Data on alternative treatments are sparse. Aims: The purpose of this study was to retrospectively evaluate outcome of microscopic colitis patients receiving anti-tumour necrosis factor therapy at our centre. Methods:Treatment results, including side effects, for all microscopic colitis patients receiving anti-tumour necrosis factor therapy were registered at week 12 and at end of follow-up. Clinical remission was defined as a mean of Results: The study cohort comprised 18 patients; mean age at diagnosis was 47 years (range 19-77). Ten and eight patients, respectively, received adalimumab and infliximab as first-line anti-tumour necrosis factor; seven patients received second-line anti-tumour necrosis factor due to non-response, loss of response or side effects. At week 12, 9/18 patients had achieved remission, 6/18 were responders and 3/18 were non-responders. Of the nine remission patients, 3/18 (16%) had long-lasting clinical remission post-induction therapy alone. Five patients (28%) (one first-line, four second-line anti-tumour necrosis factor) were in remission and one patient (6%) responded to maintenance treatment; follow-up was mean 22 (range 4-60) months. Six patients (33%) had minor, reversible side effects. Conclusions: Over half of budesonide-refractory microscopic colitis patients can achieve clinical remission or response on anti-tumour necrosis factor agents. Prospective studies are mandatory to evaluate the efficacy and safety of anti-tumour necrosis factor treatments in budesonide-refractory microscopic colitis.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Gastroenterologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Gastroenterology and Hepatology (hsv//eng)

Keyword

Microscopic colitis; biological treatment; budesonide refractory; collagenous colitis; lymphocytic colitis

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Find more in SwePub

By the author/editor
Daferera, Niki
Hjortswang, Henr ...
Ignatova, Simone
Münch, Andreas, ...
About the subject
MEDICAL AND HEALTH SCIENCES
MEDICAL AND HEAL ...
and Clinical Medicin ...
and Gastroenterology ...
Articles in the publication
United European ...
By the university
Linköping University

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view